Added to YB: 2024-11-15
Pitch date: 2024-11-14
ACRS [bullish]
Aclaris Therapeutics, Inc.
+106.36%
current return
Author Info
Stock Pursuit researches domestic deep value equities below net cash, net current asset value or net tangible assets. Sign up for the newsletter.
Company Info
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Market Cap
$710.9M
Pitch Price
$2.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.72
P/E
-9.07
EV/Sales
62.40
Sector
Pharmaceuticals
Category
value
Value Biotech/Pharma - Aclaris Therapeutics, Inc.
ACRS: Small-cap biotech at $2.44/share, $174M mkt cap vs $122M net cash. KINect platform for drug discovery. Growing revenue, multiple drugs in pipeline. Trading close to cash value. Potential upside but risky due to small-cap biotech nature.
Read full article (1 min)